About

Paul Andrews BSC (Hons) PhD FSB

me

Dr. Paul D. Andrews

Prior to establishing Stem Cell Solutions Ltd, I was Senior Scientist and Project Leader at Cellartis AB, at the time world-leader in ethically derived hES cell lines and their derivatives, with bases in Dundee, Scotland and Gothenburg, Sweden.  My team was part of a larger collaboration with Lund University in Sweden and the Hagerdorn Institute in Denmark.We had significant success in developing novel defined and xeno-free media formulations for the growth and subsequent differentiation of human embryonic stem cells into beta-cell progenitors with the long term aim for their use in the therapy of type-2 diabetes (funded by Novo Nordisk). Cellartis was acquired in 2011 by the French biotech company Cellectis.

Human stem cells

Human Feeder-free ES cells

Prior to being recruited to Cellartis, I was Senior Scientist and Team Leader in the Drug Discovery Unit (DDU), based in the internationally renowned College of Life Sciences at the University of Dundee in Scotland. In his position I led the Stem Cell Technologies team which performed a range of high content small molecule screens on human ES cells and their derivatives – a successful collaboration with Cellartis AB and 3 academic groups within Scotland, funded by ITI Life Sciences (now Scottish Enterprise). The programme was commercial in outlook and timeline/milestone driven. Building on my knowledge in the field of microscopy, I established high content screening (HCS) capabilities for the DDU and subsequently applied this to identify a portfolio of small molecules able to manipulate human ES cells fate. I acquired an in-depth understanding of the drug discovery process during this time. We were able to establish a robust platform for industry-standard screening stem cells from scratch.

Paul Andrews Nikon Small World

Two Telophase Cell Dividing (Nikon Small World Prize winner)

Prior to entering the drug discovery field, I achieved a track record in biochemistry, cell biology and high-end microscopy, mainly in oncology-related areas, in the laboratory of Jason Swedlow.

Prior to joining Jason’s lab I spent two years running a fledgling Microscope facility (centred around a DeltaVision Microscope) and therefore was exposed to a wide range of imaging techniques and cellular/organismal systems.

My focus ever since graduating from my PhD program was on understanding signalling pathways and their regulation of the cell cycle and the cytoskeleton. I have worked extensively on Aurora B protein kinase and PP1 protein phosphatase. I also have extensive experience of molecular and classical genetics using budding yeast gained over 7 years in the laboratory Michael Stark in at the University of Dundee. My PhD with David Hornby at the University of Sheffield, was concerned with the characterisation and regulation of  human DNA Methyltransferase.

Honors

2013: Elected Fellow of the Society of Biology.

Current Board/Committee Membership

Editorial Board Member: Current Research in Drug Discovery

2007- Officer for Website Coordination and Public Engagement and Trustee of the British Society for Cell Biology.

Previous Board Membership:

2012- Advisory Board Member and 2020 Vision Strategy Group member of the Scottish Stem Cell Network

Current or Previous Consultancy Experience:

  • Grant-writing, strategy, project management, scoping, due-diligence/technical assessments, purchasing and site design for the National Phenotypic Screening Centre Project – a new large national SULSA-sponsored initiative (more info here)
  • Professor Andrew Hopkins and Dr. Quentin Bickle (high content screening platform development for parasitic disease drug discovery)
  • The Principal’s Office, University of Dundee (Beacons for Public Engagement Consortium bid)
  • Applied Precision Inc. (microscope hardware/software development)

Editorial Experience: I have reviewed manuscripts for a range of high-ranking journals:
Science, Nature, Molecular Cell, Current Biology, Journal of Cell Biology, Journal of Cell Science, Oncogene, Molecular and Cellular Biochemistry, Molecular Biology of the Cell, Journal of Cell Science, Genetics, EMBO Reports, Biochemical Journal, British Journal of Cancer, Future Medicinal Chemistry, Stem Cells, Molecular Biotechnology.

Grant Reviews: I have reviewed grants for the following bodies:
Wellcome Trust
N3CR
Medical Research Scotland
Israel-Germany Cancer Fund
Austrian Science Fund (FWF)

Recent Research Publications:

  1. Andrews, P.D. (2011) Discovering Small Molecules to Control Stem Cell Fate. Future Medicinal Chem. 3, 1539-1549.
  2. Andrews, P.D.*,Becroft, M., Aspegren, A., Gilmour, J., James, M.J., McRae, S., Kime, R., Allcock, R.W., Abraham, A., Jiang, Z., Strehl, R., Mountford, J.C., Milligan, G., Houslay, M.D., Adams, D.R.,Frearson, J.A. (2010) High Content Screening of Feeder-free Human Embryonic Stem Cells to Identify Pro-Survival Small Molecules. Biochem. J.432, 21–33. * corresponding author.
  3. Andrews, P.D. (2010) The Place of Stem Cells in Drug Discovery 2.0: Technical Challenges and Biological Hurdles. Int. Drug Discovery Rev. Aug/Sept. 1-5.
  4. Andrews, P.D. (2010) Turn back the clock and be healed: Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine. Eur. Pharmaceut. Rev. 2,48-52.

Full list and citation analysis:

Google Scholar
Pubmed

Scientific Oral Presentations

Meeting Chairmanship:

  1. Cell based assays Europe Congress 2014: Paradigm Global Events, London, Feb 2014.

Workshops:

  1. Co-organised and co-delivered a 1 day workshop on Industrialisation of pluripotent stem cells for drug discovery and regenerative medicine. VisionGain Cell based Assays Conference, London, Oct. 2011.
  2. Organised and co-presented a full day workshop on Using Stem Cells in Drug Discovery with Robert Passier (Leiden) in June 2010 at the Informa Cell Based Assays Conference, Cologne, Germany.

Panel Discussions: 

  1. Stem Cells: Applications and Ethics. Oxbridge Biotech Roundtable, Manchester Business School, Nov 20th 2012.
  2. New Models of Collaboration between Academia and Industry. World Stem Cell and Regenerative Medicine Congress, London.

Recent Invited International Webinars:

  1. Stem Cells in Drug Discovery and Predictive Toxicology. Cambridge Healthtech Institute. Dec 7th 2010.

Recent International Meeting Presentations:

  1. The UK National Phenotypic Screening Centre (2014) CV7000 User Group Meeting, Strasbourg, Nov 2014
  2. Establishing a National Phenotypic Screening Capability in the UK (2014) ELRIG DD14, Manchester, UK, Sept 2014
  3. Using Phneotypic High-Content Screening to Discover Small Molecule Modulators of Stem Cell Fate. 1St Brazilian HCS Meeting, Ribeirao Preto, Brazil, April 2014.
  4. The Importance of Pluripotent Stem Cells in Drug Discovery: from Toxicology to Cell Therapy (2014) Cell based assays Europe Congress 2014: Paradigm Global Events, London, Feb 2014.
  5. Screening hES cells for Pro-survival Small Molecules (2011) World Stem Cell and Regenerative Medicine Congress, London.
  6. Using High Content Screening to Discovery Small Molecules that Control Human Embryonic Stem Cell Fate (2010) CHI Conference on Stem Cells in Drug Discovery and Development, San Diego, USA.
  7. Finding Small Molecules to Control Stem Cell Fate (2010) BSCB-BSDB Spring Meeting, University of Warwick.
  8. High Content Screening with Human Embryonic Stem Cells (2010) Lifting the Lid on Laboratory Automation Conference, Hinxton, Cambridge, UK.
  9. Discovery of Small Molecules that Control Human Embryonic Stem Cell Fate. (2010) A*Star Symposium, Biopolis, Singapore.
  10. Why High Content Screening suits Stem Cells (2009) High Content Workshop, MIPTEC 2009, Basel, Switzerland.
  11. Are we ready to use hES Cells in Drug Discovery? (2009) Informa Life Sciences: Cell Based Assays Conference, London.
  12. Putting the HCS into hESCs: identifying small molecules to control human embryonic stem cell behaviour using high content screening (2009) Select Bioscience Screening Europe Conference, Berlin, Germany.
  13. Using High Content Screening to identify small-molecule modulators of stem cell behaviour (2009) Cellular Imaging and Analysis Conference, Dublin, Eire.
  14. Drug discovery using cell-based systems: does it work and where can stem cells make a contribution (2008) Scottish Stem Cell Network Drug Discovery and Predictive Toxicology Symposium, Dundee.

Other recent UK Seminars

  1. Progress Establishing the UK National Phenotypic Screening Centre (2014) Academic Screening Group Meeting, University of Oxford.
  2. Cell Control in a Petri Dish Symposium (2012) Royal Society of Chemistry, London.
  3. Bath Centre for Regenerative Medicine Stem Cell Symposium (2011) University of Bath.
  4. Stem Cells in Drug Discovery (2007) UK Academic Screening Group Meeting, National Institute for Medical Research, London.